1 mg of tirzepatide TrimRX Microdosing Tirzepatide Chart: A Weekly
Description
Group one included patients with moderate PAD who were started on GLP-1 RAs, and group two included patients with moderate PAD who were not started on GLP-1 RAs. At one year, patients with moderate PAD who were started on GLP-1 RAs had fewer major adverse limb events (MALE) (0.8% vs 1.5%), major adverse cardiac events (MACE) (25.4% vs 29.3%), and decreased risk of hospitalizations (17.9 vs 26.8%)
The GLP-1 group showed a mean questionnaire score decrease of 4.05 points, compared to just 1.15 points in the behavioural-only group nearly four times the improvement
Lowers blood sugar levels
Integrative Anti-Aging Doctor, Rouzbeh Sattari, M.D
The GLP-1 Kitchen: A Cookbook for Living Well on Weight Loss Medications [Escobar, Dr
